Abstract
Several conceptual frameworks have been proposed to explore the underlying pathogenesis of acute heart failure (AHF), and recently emerging evidence has suggested a potential impact of microcirculatory dysfunction. Numerous experimental and clinical studies have reported that microcirculation is altered in patients with AHF and cardiogenic shock (CS), and the extent of micro-vascular abnormalities has been correlated with organ dysfunction and mortality in AHF.
Although, the clinical consequences of macro-circulatory abnormalities, congestion or hypoperfusion, can lead to organ injury and failure of target organs (i.e. heart, lungs, kidneys, liver, intestine, brain), the intermediary link between central hemodynamics and organ failure is represented by microcirculatory dysfunction. Multiple organ failure is common in AHF and CS patients, despite correction of mean arterial pressure and cardiac output. Furthermore, using global hemodynamic markers as target to therapy in AHF may not be sufficient to avoid subsequent organ failure. Direct monitoring of the microcirculation by using currently available techniques, in conjunction with global hemodynamic data can be expected to help in the understanding of the pathophysiology of microcirculatory dysfunction during AHF decompensation.
Although different treatment strategies, including pharmacological interventions and mechanical circulatory support (MCS), may theoretically improve microcirculatory dysfunction, AHF patients may present with distinct clinical condition, varying from hypertensive heart failure to CS, and the severity of microcirculatory alterations and the response to therapy may differ among these clinical conditions. Understanding the time-course of microcirculatory abnormalities during AHF decompensation may assist to guide the therapies, and may help to identify the optimal timing for MCS implant.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12(10):1076–84.
Chioncel O, Vinereanu D, Datcu M, et al. The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J. 2011;162(1):142–53 e1.
Chioncel O, Mebazaa A, Harjola VP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(10):1242–54.
Hamo CE, Butler J, Gheorghiade M, Chioncel O. The bumpy road to drug development for acute heart failure. Eur Heart J Suppl. 2016;18(suppl G):G19–32.
Chioncel O, Collins SP, Ambrosy AP, Pang PS, Radu IR, Antohi EA, Masip J, Butler J and Iliescu VA. Therapeutic Advances in the Management of Cardiogenic Shock. Am J Ther. 2019;26(2):e234–47.
Thiele H, Ohman EM, Desch S, et al. Management of cardiogenic shock. Eur Heart J. 2015;36(20):1223–30.
van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232–e68.
den Uil CA, Klijn E, Lagrand WK, Brugts JJ, Ince C, Spronk PE, Simons ML. The microcirculation in health and critical disease. Prog Cardiovasc Dis. 2008;51(2):161–70.
De Backer D, Creteur J, Dubois MJ, Sakr Y, Vincent JL. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am Heart J. 2004;147(1):91–9.
Lauten A, Ferrari M, Goebel B, Rademacher W, Schumm J, Uth O, Kiehntopf M, Figulla HR, Jung C. Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment. Eur J Heart Fail. 2011;13:711–7.
Lim N, Dubois MJ, De Backer D, et al. Do all non survivors of cardiogenic shock die with a low cardiac index? Chest. 2003;124(5):1885–91.
Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch. 2000;440(5):653–66.
Salgado DR, Favory R, De Backer D. Microcirculatory assessment in daily clinical practice – not yet ready but not too far! Einstein. 2010;8(1):107–16.
Moore JPR, Dyson A, Singer M, Fraser J. Microcirculatory dysfunction and resuscitation: why, when, and how. Br J Anaesth. 2015;115(3):366–75.
De Backer D, Ospina-Tascon G, Salgado D, Favory R, Creteur J, Vincent JL. Monitoring the microcirculation in the critically ill patient: current methods and future approaches. Intensive Care Med. 2010;36:1813–25.
Hainsworth R. Vascular capacitance: its control and importance. Rev Physiol Biochem Pharmacol. 1986;105:101–73.
Vallet B. Endothelial cell dysfunction and abnormal tissue perfusion. Crit Care Med. 2002;30:S229–34.
Daly CJ, McGrath JC. Previously unsuspected widespread cellular and tissue distribution of β-adrenoceptors and its relevance to drug action. Trends Pharmacol Sci. 2011;32:219–26.
De Backer D, Donadello K, Taccone FS, Ospina-Tascon G, Salgado D, Vincent JL. Microcirculatory alterations: potential mechanisms and implications for therapy. Ann Intensive Care. 2011;1:27.
Jung C, Ferrari M, Roediger C, Fritzenwanger M, Goebel B, Lauten A, Pfeifer R, Figulla HR. Evaluation of the sublingual microcirculation in cardiogenic shock. Clin Hemorheol Microcirc. 2009;42:141–8.
den Uil CA, Lagrand WK, van der Ent M, Jewbali LS, Cheng JM, Spronk PE, Simoons ML. Impaired microcirculation predicts poor outcome of patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2010;31(24):3032–9.
Kirschenbaum LA, Astiz ME, Rackow EC, Saha DC, Lin R. Microvascular response in patients with cardiogenic shock. Crit Care Med. 2000;28:1290–4.
Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L -arginine–nitric oxide metabolic pathway in patients with congestive heart failure. Circulation. 1999;99:2113–7.
Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz M, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19(7):821–36.
de Backer D, Hollenberg S, Boerma C, et al. How to evaluate the microcirculation: report of a round table conference. Crit Care. 2007;11:R101.
Donati A, Domizi R, Damiani E, Adrario E, Pelaia P, Ince C. From macrohemodynamic to the microcirculation. Crit Care Res Prac. 2013;2013:892710.
Gilbert-Kawai E, Coppel J, Bountziouka V, Ince C, Martin D, Caudwell Xtreme Everest and Xtreme Everest 2 Research Groups. A comparison of the quality of image acquisition between the incident dark field and side stream dark field video-microscopes. BMC Med Imaging. 2016;16(1):10.
Gomez H, Torres A, Polanco P, Kim HK, Zenker S, Puyana JC, Pinsky MR. Use of non-invasive NIRS during a vascular occlusion test to assess dynamic tissue O2 saturation response. Intensive Care Med. 2008;34:1600–7.
Levy B, Gawalkiewicz P, Vallet B, Briancon S, Nace L, Bollaert PE. Gastric capnometry with air automated tonometry predicts outcome in critically ill patients. Crit Care Med. 2003;31:474–80.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618–51.
Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail. 2011;13:37–42.
Greene SJ, Butler J, Fonarow GC, Subacius HP, Ambrosy AP, Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP, Böhm M, Chioncel O, Nodari S, Senni M, Zannad F, Gheorghiade M. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018;20(2):281–91.
Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455–69.
Lemley KV, Kriz W. Anatomy of the renal interstitium. Kidney Int. 1991;39:370–81.
Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.
Legrand M, Mebazaa A, Ronco C, Januzzi JL Jr. When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: the case of cardiorenal syndrome. Crit Care Med. 2014;42:2109–17.
Verbrugge FH, Dupont M, Steels P, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol. 2013;62:485–95.
Nagatomo Y, Wilson Tang WH. Intersections between microbiome and heart failure: revisiting the gut hypothesis. J Card Fail. 2015;21(12):973–80.
Chioncel O, Ambrosy AP. Trimethylamine N-oxide and risk of heart failure progression: marker or mediator of disease. Eur J Heart Fail. 2019;21(7):887–90.
Sundaram V, Fang JC. Gastrointestinal and liver issues in heart failure. Circulation. 2016;133:1696–703.
van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010;16:84–90.
Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Kitzberger R, Warszawska J, Holzinger U, Schenk P, Madl C. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med. 2009;35:1397–405.
Ambrosy AP, Gheorghiade M, Bubenek S, Vinereanu D, Vaduganathan M, Macarie C, Chioncel O, Romanian Acute Heart Failure Syndromes (RO-AHFS) study investigators. The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. Eur Heart J Acute Cardiovasc Care. 2013;2(2):99–108.
Wan Z, Ristagno G, Sun S, Li Y, Weil MH, Tang W. Preserved cerebral microcirculation during cardiogenic shock. Crit Care Med. 2009;37(8):2333–7.
Chioncel O, Collins SP, Ambrosy AP, Gheorghiade M, Filippatos G. Pulmonary Oedema-therapeutic targets. Card Fail Rev. 2015;1(1):38–45.
Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med. 1999;159:646–78.
Pappas L, Filippatos G. Pulmonary congestion in acute heart failure: from hemodynamics to lung injury and barrier dysfunction. Rev Esp Cardiol. 2011;64(9):735–8.
Parissis JT, Venetsanou KF, Mentzikof DG, Ziras NG, Kefalas CG, Karas SM. Tumor necrosis factor-alpha serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure. Scand Cardiovasc J. 1999;33:344–50.
Hogan CJ, Ward KR, Franzen DS, Rajendran B, Thacker LR. Sublingual tissue perfusion improves during emergency treatment of acute decompensated heart failure. Am J Emerg Med. 2012;30:872–80.
Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet. 2004;364:545–8.
TRIUMPH Investigators, Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, Hochman JS. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007;297:1657–66.
Chioncel O, Collins SP, Greene SJ, Ambrosy AP, Vaduganathan M, Macarie C, Butler J, Gheorghiade M. Natriuretic peptide-guided management in heart failure. J Cardiovasc Med (Hagerstown). 2016;17(8):556–68.
den Uil CA, Lagrand WK, Spronk PE, van der Ent M, Jewbali LS, Brugts JJ, Ince C, Simoons ML. Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure. Eur J Heart Fail. 2009;11:386–90.
den Uil CA, Caliskan K, Lagrand WK, van der Ent M, Jewbali LSD, van Kuijk JP, Spronk PE, Simoons ML. Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Med. 2009;35:1893–9.
Mebazaa A, Motiejunaite J, Gayat E, Crespo-Leiro MG, Lund LH, Maggioni AP, Chioncel O, Akiyama E, Harjola VP, Seferovic P, Laroche C, Julve MS, Roig E, Ruschitzka F, Filippatos G, ESC Heart Failure Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20(2):332–41.
De Backer D, Creteur J, Dubois MJ, et al. The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med. 2006;34:403–8.
Hernandez G, Bruhn A, Luengo C, Regueira T, Kattan E, Fuentealba A, Florez J, Castro R, Aquevedo A, Pairumani R, McNab P, Ince C. Effects of dobutamine on systemic, regionalvand microcirculatory perfusion parametersvin septic shock: a randomized, placebo v controlled, v double-blind, crossover study. Intensive Care Med. 2013;39:1435–43.
den Uil CA, Lagrand WK, van der Ent M, Nieman K, Struijs A, Jewbali LS, Constantinescu AA, Spronk PE, Simoons ML. Conventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shock. PLoS One. 2014;9(8):e103978.
Wimmer R. Effects of levosimendan onmicrocirculation in patients with cardiogenic shock. Circulation. 2008;118:s664–5.
Werdan K, Gielen S, Ebelt H, et al. Mechanical circulatory support in cardiogenic shock. Eur Heart J. 2014;35(3):156–67.
Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19(Suppl 3):S8.
Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382(9905):1638–45.
Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287–96.
Zheng XY, Wang Y, Chen Y, et al. The effectiveness of intra-aortic balloon pump for myocardial infarction in patients with or without cardiogenic shock: a meta-analysis and systematic review. BMC Cardiovasc Disord. 2016;16(1):148.
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.
Jung C, Lauten A, Rödiger C, et al. Effect of intra-aortic balloon pump support on microcirculation during high-risk percutaneous intervention. Perfusion. 2009;24(6):417–21.
Den Uil CA, Lagrand WK, Van Der Ent M, et al. The effects of intra-aortic balloon pump support on macrocirculation and tissue microcirculation in patients with cardiogenic shock. Cardiology. 2009;114(1):42–6.
Jung C, Fuernau G, de Waha S, et al. Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy. Clin Res Cardiol. 2015;104(8):679–87.
Munsterman LDH, Elbers PWG, Ozdemir A, et al. Withdrawing intra-aortic balloon pump support paradoxically improves microvascular flow. Crit Care. 2010;14(4):R161.
Lam K, Sjauw KD, Henriques JP, Ince C, de Mol BA. Improved microcirculation in patients with an acute ST-elevation myocardial infarction treated with the Impella LP2.5 percutaneous left ventricular assist device. Clin Res Cardiol. 2009;98(5):311–8.
Keebler ME, Haddad EV, Choi CW, et al. Venoarterial extracorporeal membrane oxygenation in cardiogenic shock. JACC Heart Fail. 2018;6(6):503–16.
Kara A, Akin S, Dos Reis MD, Struijs A, Caliskan K, van Thiel RJ, Dubois EA, de Wilde W, Zijlstra F, Gommers D, Ince C. Microcirculatory assessment of patients under VA-ECMO. Crit Care. 2016;20(1):344.
Yeh YC, Lee CT, Wang CH, Tu YK, Lai CH, Wang YC, Chao A, Huang CH, Cheng YJ, Chen YS. Investigation of microcirculation in patients with venoarterial extracorporeal membrane oxygenation life support. Crit Care. 2018;22(1):200.
Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. 2016;20:387.
Aissaoui N, El-Banayosy A, Combes A. How to wean a patient from veno-arterial extracorporeal membrane oxygenation. Intensive Care Med. 2015;41(5):902–5.
Akin S, Dos Reis Miranda D, Caliskan K, Soliman OI, Guven G, Struijs A, van Thiel RJ, Jewbali LS, Lima A, Gommers D, Zijlstra F, Ince C. Functional evaluation of sublingual microcirculation indicates successful weaning from VA-ECMO in cardiogenic shock. Crit Care. 2017;21(1):265.
Drakos SG, Kfoury AG, Hammond EH, et al. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol. 2010;56(5):382–91.
Sansone R, Stanske B, Keymel S, et al. Macrovascular and microvascular function after implantation of left ventricular assist devices in end-stage heart failure: role of microparticles. J Heart Lung Transplant. 2015;34(7):921–32.
Witman MA, Garten RS, Gifford JR, Groot HJ, Trinity JD, Stehlik J, Nativi JN, Selzman CH, Drakos SG, Richardson RS. Further peripheral vascular dysfunction in heart failure patients with a continuous-flow left ventricular assist device. J Am Coll Cardiol Heart Fail. 2015;3:703–11.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Clinical Case
Clinical Case
A 68 year-old male presented in ED for prolonged chest pain and shortness of breath. Onset of pain was 4 h before admission with crescendo intensity.
Vital signs collected in ED showed: SBP = 80 mmHg, HR = 100/min, Respiratory rate = 28/min, T = 36.8 °C and peripheral O2 saturation of 92%. Clinical examination focused on cardiovascular system revealed systolic murmur of mitral regurgitation 4/6 and S3 sound, pulmonary rales on both pulmonary fields, cold extremities and altered mental status.
No relevant medical history has been found for the patient, except a previous diagnosis of hypercholesterolemia and a recent Echocardiography documenting a moderate mitral regurgitation (MR).
ECG showed sinus rhythm (96/min) elevation of J point and ST elevation in V1–V5, with maximum of 8 mm in V2 (Fig. 13.5a) findings suggesting of anterior wall ST elevation myocardial infarction. Panel of biomarkers, available in 15 min since presentation, shows NT-pro-BNP = 3400 pg/ml, Hs-Troponin I = 885 ng/l and venous lactate of 5.2 mmol/l. Focus Echocardiography revealed LV global akinesia with severe MR, preserved RV function and did not detect other alternative causes of myocardial ischemia.
At this moment the diagnosis was anterior STEMI Killip IV class, and a loading dose of 180 mg Ticagrelor and 325 mg Aspirin were given to the patient.
We decided to activate the Heart Team for Cardiogenic Shock (CS) and to transfer the patient to Cath Lab. Due to hypoxia (SaO2 = 92% under 4 L Oxygen flow) and high respiratory rate (30/min), and in the context of low SBP (75–80 mmHg), we considered first of all mechanical ventilation via IOT concomitant with administration of Dobutamine 5 mcg/kg/min. Furthermore, because of persistent low SBP, Heart Team decision was to implant a short-term mechanical circulatory support before coronary intervention, and only available option in that moment was Intra-Aortic Balloon Pump (IABP). Coronary angiography revealed occlusion of the first segment of LAD and interventionist performed direct stenting on culprit lesion with TIMI 3 flow (Fig. 13.5b). After angioplasty, the patient is transferred in Intensive care Unit (ICU) with IABP support 1:1 and mechanical ventilation. ECG performed at 90 min post angioplasty revealed resolution with more than 50% of ST elevation in V2 (Fig. 13.5a). BP was 85/45 mmHg and urinary output (via bladder catheter) was 30 ml/h. In ICU, information provided by Echocardiography confirmed severe MR, with LVEF 25% and good RV function (Fig. 13.5c). Blood lactate was 5.8 mmol/l and the result of other blood sample collected in ED showed Hemoglobin = 12.9 g/dl, WBC = 12,400/mm3, CK-MB = 76 serum creatinine = 1.9 mg/dl, ALT = 45UI/L, AST = 58UI/L, GGT = 71UI/L. A Swann-Ganz catheter was inserted and this option was determined by the need to adequately monitor hemodynamic parameters in a STEMI with IABP and persistent hypoperfusion secondary to CS. Invasive hemodynamic data showed Cardiac Index (CI) = 1.7 l/min/m2, Pulmonary Capillary Wedge Pressure (PCWP) = 24 mmHg, Systemic Vascular Resistances (SVR = 21 Wood units) and Central Venous Pressure (CVP) = 14 mmHg (Fig. 13.6). IV vasoactive treatment included Dobutamine 7 mcg/kg/min and Furosemide 4 mg/h and it was continued for the next 18 h.
Chest X-ray detected moderate cardiomegaly, redistribution with upper vessel enlargement, perihilar haze, and bilateral pulmonary infiltrates (Fig. 13.5d).
In the day 2 in ICU, hemodynamic data showed increased of CI, but a substantial decrease in SVR (10 Wood units). This finding, in conjunction with worsening of multi-organ injury and radiological findings were supportive for the occurrence of Systemic Inflammatory Syndrome (SIRS) and dictated initiation of IV vasoconstrictor Norepinephrine at doses of 0.3 and then 0.5 mcg/kg/min. In the day 3, SBP was constantly higher than 95 mmHg with urinary output of 100 ml/h, CI increased at 2.4 l/min/m2 and PCWP ranged between 15 and 17 mmHg (Fig. 13.6). Furthermore, blood lactate decreased at 2.2 mmol/l. TTE reported decreasing severity of MR. Dobutamine dose decreased at 5 mcg/kg/min. However, despite of the improving of the hemodynamics and of the global metabolic deficit, multi-organ injury remains persistent. During day 4, SBP and urinary output increased comparative with previous days and SVR increased toward normal value (1–14 Wood units) (Fig. 13.6). Blood lactate was 1.7 mmol/l. Norepinephrine dose was decreased and then stopped while Dobutamine dose has remained unchanged. Even if multi-organ injury continued to evolve, IABP assistance was switched from 1:1 to 2:1, without significant variations in SBP and without decrease of sub-aortic velocity time integral (VTI) at Echo. In the day 5, clinical examination reported no evident clinical signs of hypoperfusion and only mild congestion (basal pulmonary rales). All hemodynamic parameters have entered in normal range and to note, markers of organ dysfunction improved. IABP was switched at 3:1 during the next 6 h and then stopped. Dobutamine dose decreased at 2 mcg/kg/min. In the day six patient was transferred in Cardiology Unit. In Cardiology, the patient has been monitored clinically, ECG and biologic. Echocardiography demonstrated a substantial improvement in global contractility with EF = 35–37% and MR remained moderate. The markers of organ injury further decreased during hospitalization, but without attaining the normal values. The therapies with ACE-inhibitors and beta-blocker was initiated as soon as the patient became stable.
The patient was discharged in day 13 without signs of residual congestion and with a very good mobility. The patient and family have been instructed for effort and dietetic regimen, and a follow up visit at 2 weeks post discharge has been planned.
Comments
The clinical case is very illustrative for the in-hospital course of post MI-CS associated with SIRS and multi-organ injury (kidney, liver and lung). Multi-organ injury is the consequence of the various degree of microvascular abnormalities, and actually microcirculatory dysfunction is the main facilitator of organ injury/failure in CS.
In this case, the time course of microcirculatory alterations during hospitalization was longer than abnormalities in macro-hemodynamics, and tissue perfusion remained altered even after achievement of within-target cardiac index and SBP. In D3, D4 and D5 was a disconnection between improving in hemodynamic measurements and markers of organ injury.
Notably, although in this case revascularization has been associated to re-establishing of coronary microcirculatory perfusion, suggested by TIMI 3 flow and a >50% resolution of ST elevation, recovery of LV function is a long term process, unable to prevent early occurrence of multi-organ injury. In addition, the microcirculatory dysfunction initiated by systemic hypoperfusion to other organs may evolve independent of central hemodynamics.
Mechanical circulatory support (MCS) device has been used to reverse hemodynamic abnormalities and to maintain organ perfusion. Despite of the recent evidences showing limited outcome benefit, IABP remained the most utilized MCS. IABP has shown to improve coronary blood flow by augmenting coronary diastolic blood pressure and increasing cardiac index by reducing left ventricular afterload. These effects have been proved very useful in a patient with large anterior MI, where a substantial area of stunning may be responsible of persistent LV dysfunction despite of prompt revascularization, and furthermore in conditions of severe MR, potentially improved by decreasing afterload.
However, correction of global hemodynamic parameters by IABP did not cause a parallel improvement in microcirculatory perfusion and oxygenation of the organ systems, a condition referred to as a loss of hemodynamic coherence between macro- and microcirculation.
Beyond of technical success, reflected by improvement of macro-hemodynamics, preventing or limiting progression of microcirculatory dysfunction by MCS devices is a key factor responsible for improvement of outcome in patients with CS, and preservation of microcirculation with adequate tissue perfusion rather than maintenance of more normal arterial pressure is the crucial determinant of outcome.
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chioncel, O., Mebazaa, A. (2020). Microcirculatory Dysfunction in Acute Heart Failure. In: Dorobantu, M., Badimon, L. (eds) Microcirculation. Springer, Cham. https://doi.org/10.1007/978-3-030-28199-1_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-28199-1_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-28198-4
Online ISBN: 978-3-030-28199-1
eBook Packages: MedicineMedicine (R0)